Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?

Although several viruses can easily infect the central nervous system (CNS), antiviral drugs often show dramatic difficulties in penetrating the brain from the bloodstream since they are substrates of active efflux transporters (AETs). These transporters, located in the physiological barriers betwee...

Full description

Bibliographic Details
Main Authors: Alessandro Dalpiaz, Barbara Pavan
Format: Article
Language:English
Published: MDPI AG 2018-03-01
Series:Pharmaceutics
Subjects:
Online Access:http://www.mdpi.com/1999-4923/10/2/39
id doaj-7a8b1597c93441c2a6284fb5b42d1ed5
record_format Article
spelling doaj-7a8b1597c93441c2a6284fb5b42d1ed52020-11-24T22:00:04ZengMDPI AGPharmaceutics1999-49232018-03-011023910.3390/pharmaceutics10020039pharmaceutics10020039Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?Alessandro Dalpiaz0Barbara Pavan1Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 44121 Ferrara, ItalyDepartment of Biomedical and Specialist Surgical Sciences, University of Ferrara, 44121 Ferrara, ItalyAlthough several viruses can easily infect the central nervous system (CNS), antiviral drugs often show dramatic difficulties in penetrating the brain from the bloodstream since they are substrates of active efflux transporters (AETs). These transporters, located in the physiological barriers between blood and the CNS and in macrophage membranes, are able to recognize their substrates and actively efflux them into the bloodstream. The active transporters currently known to efflux antiviral drugs are P-glycoprotein (ABCB1 or P-gp or MDR1), multidrug resistance-associated proteins (ABCC1 or MRP1, ABCC4 or MRP4, ABCC5 or MRP5), and breast cancer resistance protein (ABCG2 or BCRP). Inhibitors of AETs may be considered, but their co-administration causes serious unwanted effects. Nasal administration of antiviral drugs is therefore proposed in order to overcome the aforementioned problems, but innovative devices, formulations (thermoreversible gels, polymeric micro- and nano-particles, solid lipid microparticles, nanoemulsions), absorption enhancers (chitosan, papaverine), and mucoadhesive agents (chitosan, polyvinilpyrrolidone) are required in order to selectively target the antiviral drugs and, possibly, the AET inhibitors in the CNS. Moreover, several prodrugs of antiretroviral agents can inhibit or elude the AET systems, appearing as interesting substrates for innovative nasal formulations able to target anti-Human Immunodeficiency Virus (HIV) agents into macrophages of the CNS, which are one of the most important HIV Sanctuaries of the body.http://www.mdpi.com/1999-4923/10/2/39active efflux transporterantiretroviral drugHIV sanctuariesthermoreversible gelnano-emulsionpolymeric microparticlespolymeric nanoparticlesnasal formulationsolid lipid microparticlesvirus
collection DOAJ
language English
format Article
sources DOAJ
author Alessandro Dalpiaz
Barbara Pavan
spellingShingle Alessandro Dalpiaz
Barbara Pavan
Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?
Pharmaceutics
active efflux transporter
antiretroviral drug
HIV sanctuaries
thermoreversible gel
nano-emulsion
polymeric microparticles
polymeric nanoparticles
nasal formulation
solid lipid microparticles
virus
author_facet Alessandro Dalpiaz
Barbara Pavan
author_sort Alessandro Dalpiaz
title Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?
title_short Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?
title_full Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?
title_fullStr Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?
title_full_unstemmed Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?
title_sort nose-to-brain delivery of antiviral drugs: a way to overcome their active efflux?
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2018-03-01
description Although several viruses can easily infect the central nervous system (CNS), antiviral drugs often show dramatic difficulties in penetrating the brain from the bloodstream since they are substrates of active efflux transporters (AETs). These transporters, located in the physiological barriers between blood and the CNS and in macrophage membranes, are able to recognize their substrates and actively efflux them into the bloodstream. The active transporters currently known to efflux antiviral drugs are P-glycoprotein (ABCB1 or P-gp or MDR1), multidrug resistance-associated proteins (ABCC1 or MRP1, ABCC4 or MRP4, ABCC5 or MRP5), and breast cancer resistance protein (ABCG2 or BCRP). Inhibitors of AETs may be considered, but their co-administration causes serious unwanted effects. Nasal administration of antiviral drugs is therefore proposed in order to overcome the aforementioned problems, but innovative devices, formulations (thermoreversible gels, polymeric micro- and nano-particles, solid lipid microparticles, nanoemulsions), absorption enhancers (chitosan, papaverine), and mucoadhesive agents (chitosan, polyvinilpyrrolidone) are required in order to selectively target the antiviral drugs and, possibly, the AET inhibitors in the CNS. Moreover, several prodrugs of antiretroviral agents can inhibit or elude the AET systems, appearing as interesting substrates for innovative nasal formulations able to target anti-Human Immunodeficiency Virus (HIV) agents into macrophages of the CNS, which are one of the most important HIV Sanctuaries of the body.
topic active efflux transporter
antiretroviral drug
HIV sanctuaries
thermoreversible gel
nano-emulsion
polymeric microparticles
polymeric nanoparticles
nasal formulation
solid lipid microparticles
virus
url http://www.mdpi.com/1999-4923/10/2/39
work_keys_str_mv AT alessandrodalpiaz nosetobraindeliveryofantiviraldrugsawaytoovercometheiractiveefflux
AT barbarapavan nosetobraindeliveryofantiviraldrugsawaytoovercometheiractiveefflux
_version_ 1725845627746648064